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Renal formation of the vasoconstrictor prostaglandins 
thromboxane A2 (TXA2) and prostaglandin F2~ (PGF2~) was 
investigated in 25 patients with cardiac failure, divided into 
New York Heart Association functional classes I to IV, and 
in eight healthy control subjects. Plasma renin activity (PRA) 
and hemodynamic parameters were also investigated. Renal 
vasoconstrictor eicosanoid formation, measured in urinary 
daily excretion, was not different between patients in class 
I and control subjects. Class II to IV patients showed 
progressively increasing production of PGF2~ (F = 49.8, 
p < 0.001, analysis of variance) and TXA2 (F = 37.8, p < 0.002). 
PGF2~ excretion peaked in class IV (+1266% vs class I, 
p<0.001). Compared with class I, urinary excretion of 
thromboxane B2 was +816% in class III and +1561% in class 
IV (both p < 0.001). PRA was significantly increased only in 
class IV (+1558%, p < 0.001). The current results indicate a 
progressive increase in renal production of vasoconstrictor 
eicosanoids directly related to New York Heart Association 
class and suggest that these prostanoids may have a role in 
deterioration of renal function. (Am Heart J 1997;133:94- 
100.) 
The long-term outcome of patients with congestive 
heart failure (CHF) depends on progressive deterio- 
ration of ventricular performance and on neurohor- 
monal reactions et in motion by the disease. 1 Sym- 
pathetic activation and enhanced activity of different 
vasoconstrictor systems, including the renin-angio- 
tensin system and vasopressin, play a major role in 
maintaining perfusion pressure and blood volume. 2
The increased formation of vasoconstrictive media- 
tors is associated with enhanced formation of vasodi- 
lating factors, such as atrial natriuretic peptide and 
renal prostaglandins E2 and I2. 3, 4 Their increase pre- 
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vents the deleterious effect of a nonmodulated vaso- 
constrictor system and maintains renal filtration. 4
Whereas the synthesis ofvasodilating eicosanoids 
is known to increase in heart failure, 4the renal syn- 
thesis of vasoconstrictive prostanoids (i.e., prosta- 
glandin F2~ [PGF2J and thromboxane A2 [TXA2]) 
has not yet been investigated in cardiac failure 
despite their relevant vasoconstrictor activity. In 
animal studies, PGF2~ has been shown to facilitate 
the response of sympathetic nerve stimulation and to 
increase responsiveness to norepinephrine. 5 More- 
over, when systemically injected, it provokes an in- 
crease in blood pressure in animals and in human 
beings. 6 TXA2 exhibits very potent constrictive f- 
fects in different vascular beds, including the renal 
bed, and within the kidney it causes a decrease in 
renal blood flow and glomerular filtration rate. 7 
Thus, although in healthy subjects neither TXA 2 nor  
PGFu~ seems to be involved in the maintenance of 
renal function, 6, s their enhanced renal formation, 
particularly that of TXAu, may play a significant role 
in reducing renal perfusion and glomerular filtration 
in pathologic ircumstances. 9, 10 
The TXA 2 and PGF2~ synthesized by the kidney 
are excreted in the urine as thromboxane B2 (TXB2) 
and PGF2~. Therefore renal production of these 
prostaglandins can be evaluated by measuring their 
urinary excretion. 11, 12 The aim of this study was to 
investigate the role of renal TXA2 and PGF2~ in pa- 
tients affected by CHF with different degrees of dis- 
ease severity according to New York Heart Associa- 
tion (NYHA) classification. 13
METHODS 
Study subjects and patient selection. Twenty-five 
women affected by CHF (aged 28 to 79 years; mean age 
46 _+ 33 years) and 8 healthy, age-matched female control 
subjects (aged 26 to 82 years; mean age 51 _+ 25 years) 
were studied. Only female subjects were studied because 
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renal prostaglandins were to be measured in urine, which 
may have an extrarenal origin in males. 14 None of the 
subjects was taking oral contraceptives. Patients were 
considered eligible for the study ifCHF had been diagnosed 
by clinical examination or by echocardiographic or other 
instrumental evaluation (chest radiography orcardiac ra- 
dioisotopic scanning). Exclusion criteria included iabetes, 
hypertension, liver disease, or malignant neoplasm as well 
as any primary or secondary cause of renal disease accord- 
ing to the results of clinical examination orof renal ultra- 
sound examination with serum creatinine levels at ->2.0 
mg/dl and positive results on urinalysis. The types of heart 
disease underlying cardiac failure and their percentages in 
the different classes are described in Table I. Patients were 
subdivided into four functional classes. 13 All subjects 
refrained from taking nonsteroid antiinflammatory drugs 
for 15 days before being examined. All subjects gave their 
informed consent before participating in the study. 
Study protocol 
Experimental procedure. In all patients, diuretic agents 
and angiotensin-converting e zyme inhibitors were with- 
drawn 48 hours before urine collection. Patients of class IV 
received close clinical surveillance. Among class IV pa- 
tients, only those whose condition had remained stable af- 
ter the 12-hour drug withdrawal period were admitted into 
the study and completed the 48-hour washout period 
according to the study protocol. 
For the total period of hospitalization, the subjects 
received a diet that contained 108 mmol sodium chloride 
and 60 to 80 mmol potassium per day. Daily water intake 
was measured and controlled. At admission, after a 48- 
hour period of pharmacologic washout, 24-hour urine 
samples were collected for eicosanoid (urinary PGF2~ and 
urinary TXB2), creatinine, and electrolyte (sodium and po- 
tassium) determinations. Venous blood samples were col- 
lected for serum electrolyte, serum creatinine, and plasma 
renin activity (PRA) determinations at 8:00 AM after over- 
night bed rest. Glass tubes devoid of anticoagulants 
(Vacutainer Systems, Becton Dickinson, Heylan Cedex, 
France) were used to collect he blood for serum electrolyte 
and creatinine determinations; blood samples for PRA 
were collected in cold glass tubes that contained 0.037 
mol/L ethylendiamine t tracetic acid. Urinary collection 
and blood sampling were repeated whenever changes in 
clinical findings indicated that the patient's functional 
NYHA class had changed. 
Systemic hemodynamic parameters. Arm blood pressure 
was measured with a sphygmomanometer. Thefirst Ko- 
rotkoff sound was taken as an index of systolic blood pres- 
sure (SBP) and the fifth as an index of diastolic blood pres- 
sure (DBP). Mean blood pressure was obtained by adding 
one third of the pulse pressure to the value of the diastolic 
pressure. An average of six blood pressure and heart rate 
recordings (measured at 6:00, 8:00, and 12:00 AM and at 
4:00, 8:00, and 12:00 PM) was taken as an index of the 24- 
hour study period. If tricuspid regurgitation was present, 
mean pulmonary artery pressure (PAPm) was determined 
by Doppler echocardiography according to the method e- 
scribed by Currie et al., 15 given that values thus obtained 
correlate well with those from invasive techniques. Only 
when tricuspid regurgitation was not present, PAPm was 
calculated by estimating pulmonary acceleration time, 
which has been shown to be directly and strongly corre- 
lated with PAPm.16 Venous pressure (VP) was determined 
by a direct method. 17 Pressure values were expressed as 
centimeters ofwater and were then converted into milli- 
meters of mercury by dividing by a factor of 1.36. The val- 
ues obtained by this method exhibit a high degree of cor- 
relation with the measurements in the right atrium as ob- 
tained by heart catheterization. 17 
Sodium balance and volume status. Variations in water 
and sodium metabolism were assessed uring the hospi- 
talization period by daily evaluation of serum and urinary 
electrolytes ( odium and potassium), patient weight, and 
water balance. Urinary and serum sodium and potassium 
were measured with a flame photometer (System 243 In- 
strumentation Laboratory, Lexington, Mass.). 
Plasma renin activity. PRA was determined by radioim- 
munoassay with a commerci[ally available kit (Angiotensi- 
na RIA CT, RADIM, Rome, Italy) according to Haber et 
al.ls The intraassay coefficient of variation was 7.5% at 2.3 
pg/ml, 5.4% at 8.8 pg/ml, and 9.9% at 13.5 pg/ml. The in- 
terassay coefficient of variation was 7.7% at 2.6 pg/ml, 
8.1% at 8.6 pg/ml, and 11.5% at 13 pg/ml. The detection 
limit of the method is 0.15 ng/ml/hr, and the standard 
curve ranges between 0~15 and 50 ng/ml/hr. 
Urinary prostaglandin assay. Immediately after collec- 
tion, the urine was frozen and stored at -20 ° C until 
extraction and purification procedures could be performed. 
Renal PGF2~ and TXB2 were measured by radioimmu- 
noassay after extraction from urinary samples by using an 
organic solvent and chromatographic purification in a si- 
licic acid column. Details of the method have been reported 
elsewhere.19 Carlo Patrono (Istituto di Farmacologia, Uni- 
versit~ di Chieti, Italy) provided the antibodies to PGF2~, 
obtained from the guinea pig. The antibody to TXB2 was 
provided by Luciano Caprine (Istituto di Igiene, Universit~ 
Cattolica del Sacro Cuore, Rome, Italy). The average cal- 
culatedrecoverywas 58% -+ 15% for PGF2~ and 60% _+ 10% 
for TXB2. The intraassay and interassay coefficients of 
variation were 9% and 10%, respectively. The data are ex- 
pressed as picograms per gram urinary creatinine (UCr) 
per 24-hour period. Normalization was aimed at correcting 
any change in renal function in the various study groups. 
Statistical analysis. Results are expressed as mean 
values -+ SD. Student  test was used to compare healthy 
subjects with patients of NYHA class I. Comparison among 
patient groups was performed by analysis of variance 
(ANOVA). Simple linear correlation (Pearson) was used to 
evaluate the relation among variables. If a variable was 
found to be significantly related to multiple dependent 
variables on linear correlation analysis, multiple regres- 
sion analysis was carried out to rule out spurious correla- 
tions and to assess the best relation between different 
predictor variables and a dependent variable. Statistical 
significance was set at p < 0.05. 
RESULTS 
No significant differences in hemodynamics, uri- 
nary volume, or ur inary electrolytes were found be- 
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Etiology 
Ischemic hear t  disease n = 15 (60%) 
Dilated cardiomyopathy n = 6 (24%) 
Valvular  hear t  disease n = 4 (16%) 
NYHA class 
I (u = 6) H (n = 6) I I I  (n = 7) IV (n=6)  
Pat ient  characterist ics 
Blood urea  nitrogen (mg/dl) 
Serum creatinine (mg/dl) 
Serum sodium (mmol/dl) 
Medication at t ime of 48 hr  washout  
Digoxin (0.125-0.25 mg uid) 
Furosemide (25 mg orally from u]d to bid) 
Potass ium canrenoate (100 mg orally bid) 
Captopri l  (25 mg uid) 
Ramipri l  (2.5-5 mg uid) 
0.5 -+ 0.09 0.3 -+ 0.06 0.4 -- 0.04 0.9 +- 0.05 
1,20 -+ 0.28 0.96 +- 0.19 1.15 +- 0.13 1.46 -+ 0.27 
140.7 -+ 2.4 139.6 -+ 2.3 138.8 -+ 4.8 137.7 -+ 3.2 
50% 66.7% 85.7% 83.3% 
16.7% 16.7% 85.7% 100% 
16.7% 33.3% 57.1% 50% 
0% 16.7% 28.6% 66.7% 
16.7% 0% 0% 0% 
bid, Two times per day. 
uid, Once a day. 
*According to clinical status. 
Tab le  ]]. Hemodynamic variables among NYHA classes 
I (n = 6) H (n = 6) 
NYHA class 
I I I  (n = 7) 1V(n=6) 
ANOVA for all pat ient groups 
F p Value 
SBP (mm Hg) 127.5 _+ 3.5 126.9 -+ 26.6 
DBP (mm Hg) 75 + 7 72.5 -+ 10.7 
PAPm (ram Hg) 28.8 _+ 8.2 30.5 +- 5.4 
I 
I 
VP (ram Hg) 5.2 -+ 1.8 7.1 _+ 1.6 
126.9 _+ 10.3 
73.7 _+ 10.3 
41.7 _+ 10.4" 
$ ] 
§ 
115 t 12.9 0.45 NS 
78.7 + 13.1 0.30 NS 
58.8 _+ 9.9t 14.7 <0.001 
l § I 
9.2 _+ 2.9* 11.9 _+ 5.0t 
i $ I 
5.2 <0.03 
NS, Not significant. *p < 0.03, tp < 0.001 vs class I by Duncan ANOVA. 
Sp < 0.03 and §p < 0.001 between classes by Duncan ANOVA. 
tween healthy subjects and patients of NYH class 
I (data not shown). SBP and DBP were similar in all 
patient groups (Table II). In healthy control subjects, 
average PGF2~ urinary excretion was 374.8 _+ 176.7 
pg/gm UCr/24 hr and was not significantly different 
from that observed in class I patients (148.2 +_ 52.6 
pg/gm UCr/24 hr). Urinary excretion of PGF2~ was 
significantly increased in class II patients compared 
with healthy control subjects and class I patients 
(+290%, p < 0.03) (Table III and Fig. 1). Urinary ex- 
cretion of PGF2~ was higher in class III and IV 
patients than in class I patients (+835%, p < 0.001 
and +1266%, p < 0.001, for classes III and IV, respec- 
tively) and higher than in class II patients (+139.6%, 
p < 0.001 and +250%, p < 0.001, for classes III and IV, 
respectively). Thus greater disease severity by NYHA 
functional class was associated with a progressive and 
significant increase in PGF2~ excretion (F =49.8, 
p < 0.001, by ANOVA) (Table III and Fig. 1). 
The average TXB 2 urinary excretion in control 
subjects was 98.1 +_ 54.1 pg/gm UCr/24 hr. This 
value was not significantly different from that either 
in class I patients (58.2 _+ 43.3 pg/gm UCr/24 hr) or 
in class II patients (214.3 _+ 168 pg/gm UCr/24 hr) 
(Table III and Fig. 1). Urinary excretion of WXB 2 was  
markedly higher in class III patients (+816%, 
p < 0.001 vs class I patients; +149%, p < 0.002 vs 
class II patients) and even more so in class IV 
patients (+1561%, p < 0.001 vs class I patients; 
+351%, p < 0.001 vs class II patients). Thus, with 
greater disease severity according to NYHA class, 
TXB 2 excretion was progressively higher (F = 37.8, 
p < 0.001) (Table III). 
In NYHA class III and IV patients, urinary TXB2 
was linearly related to PAPm (r = 0.62, p < 0.02) and 
PRA (r = 0.67, p < 0.01) (Fig. 2). 
A progressive increase in PAPm and VP was also 
found in relation to functional class. The increase 
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Fig. 1. UrinaryvasoconstrictiveprostaglandinsvsNYHA 
class. UPGF2~, Urinary prostaglandin F2~; UTXB2, uri- 
nary thromboxane B2. *p < 0.03 and ***p < 0.001 vs pa- 
tients of NYHA class I (ANOVA). Individual values are 
shown as solid circles; mean values are open circles. 
was significant in NYHA class III and even more 
significant in class IV patients (PAP m and VP, 
p < 0.001 vs class I patients) (Table II and Fig. 3). 
Urinary volume decreased in class III and IV pa- 
tients in comparison with control subjects and class 
I patients (p < 0.03 for classes III and IV vs class I 
patients) (Table III). Urinary sodium was lower only 
in class III and IV patients (p < 0.03 and p < 0.002 
respectively vs class I patients). 
There was a consistent trend toward higher values 
of PRA in relation to greater severity by functional 
class, but the increase was significant only in class IV 
patients (p < 0.001 vs class I patients) (Table III). 
Multiple regression analysis indicated that uri- 
nary PGF2~ was positively related to PAP m ([3 = 0.65, 
p < 0.001), but not to VP (Fig. 4). Renal excretion of 
TXB2 correlated with PAPm (~ = 0.61,p < 0.001) and 
more weakly with VP (~ = 0.33, p < 0.04) (Fig. 4). 
Neither urinary PGF2~ nor TXB2 was related to SBP 
or DBP. 
DISCUSSION 
Results of this study indicate for the first time that 
renal excretion of vasoconstrictor eicosanoids PGF2~ 
and TXB2 is enhanced in patients with cardiac fail- 
ure and parallels the severity of heart disease as 
evaluated by clinical data and PAPm measurement. 
The increase in PGF2~ excretion was already evi- 
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Fig. 2. Regression analysis of relation between PAPm and 
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dent in class II patients, whereas TXB2 excretion 
showed noteworthy increases only in class III and IV 
patients. However, both eicosanoids showed astrong 
correlation with PAPm (~ = 0.85,p < 0.001 for PGF2~; 
= 0.80, p < 0.001 for TXB2) , suggesting that the 
progressive impairment of cardiocirculatory func- 
tion may be important in causing increases in vaso- 
constrictor renal eicosanoid formation. 
Because urinary excretion of PGF2~ and WXS 2 re -  
f lec t  their renal synthesis TM12 and increased forma- 
tion of the vasodilating prostaglandins, prostaglan- 
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Tab le  ill. Hormonal variables, diuresis, and sodium among NYHA classes 
I (n = 6) H (n = 6) 
NYHA class 
ANOVA for all 
pat ient groups 
I I I  (n = 7) IV  (n = 6) F p Value 
Ur inary  PGF2~ (pg/gm UCr/24 hr) 
Ur inary  TXB2 (pg/gm UCr/24 hr) 
PRA (ng/L/hr) 
Ur inary  volume (ml/24 hr) 
Ur inary  sodium (mmo]/24 hr) 
148.2 ± 52.6 578.3 
L 
] 
103.8" 1385.6 ± 245.55 2023.7 ± 522.45 49.8 
§ l 
§ I 
58.2 -+ 43.3 214.3 -+ 168.0 
I 
I 
1.9 -- 1.3 2.3 +_ 3.4 
I 
1008.3 +_ 156.3 850.0 _+ 327.1 
100.0 _+ 27.9 86.2 _+ 34.2 
1 
I 
i § i 
533.1 _+ 174.65 966.7 ± 202.35 
II I 
§ t 
<0.001 
37.8 <0.001 
t § I 
7.0 _+ 4.1 31.5 _+ 15.1$ 19.2 <0.001 
I 
I ~ J 
614.3 + 254.5* 608.3 -+ 241.7" 3.69 <0.03 
55.3 _+ 19.4" 50.3 -+ 10.6~ 5.93 <0.004 
§ 
§ 
*p < 0.03, tP < 0.002, Sp < 0.001 vs class I by Duncan ANOVA. 
§p < 0.03, ] ]p < 0.002, ~ < 0.001 between classes by Duncan ANOVA. 
din I2 and prostaglandin E2 (PGE2), have already 
been reported in severe congestive heart failure, 4 the 
current results indicate that renal prostaglandin 
system is globally involved in heart failure. 
Increased renal formation of PGF2~ and TXA 2 may 
be pathophysiologically relevant in cardiac failure. 
Biologic activity of renal prostaglandins i finely 
compartmentalized in the kidney and depends on the 
capacity of cyclooxygenase activity at the site of 
eicosanoid formation and on the potential of pros- 
taglandin inactivation by prostaglandin dehydroge- 
nases in renal compartments. 2° This functional or- 
ganization may explain the very precise localization 
of their renal activity. 
PGF2~ formation is widely and homogeneously 
distributed among all renal structures, except he 
renal arteries, 21 and its inactivation takes place 
preferentially at the cortical level. 2° As a conse- 
quence, PGF2, may lead to a redistribution of renal 
blood flow from the more superficial nephrons to- 
ward the juxtamedullary nephrons that exhibit the 
greatest sodium reabsorption. 22PGF2~ acts as a vas- 
oconstrictor; there is little evidence of any diuretic 
and natriuretic activity. 23 Therefore increased renal 
formation of PGF2~ may result in enhanced sodium 
retention as a consequence of its vasoconstrictor ac- 
tivity on more superficial cortical nephrons. The in- 
creased PGF2~ formation in patients of NYHA class 
II with its consequent slightly antinatriuretic effects 
probably contributes to the maintenance ofeffective 
plasma volume even during the early phases of heart 
disease and then during the more advanced stages 
with progressively increasing PGF2~ formation. 
Under physiologic onditions, renal production of 
TXA2 is less than PGF2~ formation, and it occurs 
mainly in the glomeruli. 24 Molecular biologic studies 
have indicated that thromboxane receptors are lo- 
calized primarily within the mesangial cells 25 and in 
the smooth-muscle c lls of the afferent and efferent 
arterioles26: in this way TXA2 affects glomerular fil- 
tration rate both hemodynamically and through a 
reduction in the ultrafiltration coefficient. Renal 
TXA2 acts preferentially at the preglomerular level 
by selective constriction of the afferent artery, thus 
leading to a decrease both in effective renal plasma 
flow and in glomerular filtration rate. 27 Increased 
TXA2 renal formation, as found in class III and IV 
patients, results in a marked antidiuretic and antin- 
atriuretic effect hat potentially can help to maintain 
blood volume by reducing renal blood flow and the 
glomerular filtration ra tes  However, detrimental 
effects on renal function can easily ensue because of 
the marked decrease in glomerular filtration. Thus, 
from the pathophysiologic point of view, increased 
renal formation of PGF2~ and TXA2 may result in 
augmented renal vasoconstriction and sodium re- 
tention, which may be transitorily useful with regard 
to effective blood volume but ultimately may be dan- 
gerous in relation to renal function. 
No conclusions can be drawn regarding the mech- 
anisms responsible for the enhanced renal formation 
of PGF2~ and TXA2. The increased formation of these 
prostanoids eems to reflect the progressive activa- 
tion of the various renal vasoconstrictor systems. 
The earlier increase in PGF2~ formation (present in 
class II patients) than in TXA2 suggests that two 
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p + se R 2 p 
PAPm 0.65 :t: 0.18 0.44 < 0.001 
VP 0.29 4- 0.18 0.41 ns 
SBP 0.04 :t: 0.18 0.46 ns 
DBP -0.14 ± 0.19 0.47 ns 
Dependent variable PGF,o 
~o • 
1 
200|| j y O  
l! I0 20 30 40 50 60 70 
PAPm ~mHg)  
p+se  R 2 p 
PAPm 0.61 :t: 0.15 0.44 < 0.001 
VP 0.33 :t: 0.15 0.41 < 0.04 
SBP -0.04 ± 0.15 0.46 ns 
DBP 0.02 ± 0.16 0.47 ns 
Dependent variable UTXB2 
16011 
,, _ mee 
0 lid 20 30 40 ~! 60 70 
PAPm (mmHg) 
Fig, 4. Stepwise multiple regression analysis of relations between hormonal and hemodynamic factors in 
all patients. UPGF2~, Urinary prostaglandin F2a; UTXB2, urinary thromboxane B2. ~, Multiple regression 
coefficient. 
distinct mechanisms may be operating. The progres- 
sive lowering of cardiac output is considered to be 
responsible for the boosting of a broad spectrum of 
vasoconstrictor mechanisms, including the sympa- 
thetic nervous system, renin-angiotensin system, 
vasopressin, and endothelin systems, 4 2s each of 
which is able to activate arachidonic acid metabolism 
directly. 29,3° The sympathetic activation in the 
course of cardiac failure 4 is probably responsible for 
the early increase in PGF2~ formation. Catechola- 
mines are able to enhance the activity of phospholi- 
pase A and as a consequence to activate the arachi- 
donic acid metabolism causing the global increase in 
renal formation of PGF2~, PGE2, and prostaglandin I2
(PGI2). 29 At this early phase of heart failure, the acti- 
vation of the renal prostaglandin systems till seems to 
be well balanced between vasodilating PGI2 and PGE2 
and the vasoconstrictor PGF2~ because TXA 2 forlTla- 
tion was found to occur in the later stages (class III and 
especially class IV)(Table III and Fig. 1). 
After activation of arachidonic acid, PGF2~ can be 
formed directly from prostaglandin H2 either by a 
reductase 31or through the transformation of PGE2 
to PGF2~ by PGE2-9-ketoreductase. 32 In addition, 
transformation ofprostaglandin D2 by ll-ketoreduc- 
tase gives rise to an epimer of PGF2~, 9~,ll~-PGF2~, 
that has been found in human beings. 33 This pros- 
taglandin cross reacts with antisera to PGF2~ and 
may contribute to the increase in PGF2~ excretion. The 
increased renal TXA2 formation may have been due 
only in part to the activation of arachidonic acid 
metabolism by catecholamines because TXA2 produc- 
tion in class II patients was not different from class I. 
The enhanced formation of angiotensin II and 
probably endothelin may have been responsible for 
the increased production of renal TXA2. Both of these 
vasoconstrictor hormones have been reported to 
cause TXA 2 formation by selectively acting on spe- 
cific receptors linked to phospholipase C. 34 Our 
patients with higher TXB2 excretion were found to 
have higher PRA and PAPm values. Likewise, plasma 
endothelin concentration i patients with CHF has 
been shown to be closely related to pulmonary artery 
pressure values. 28 
In our study, PRA was significantly increased only 
in class IV patients. Our observations confirm and 
extend the findings of others who have shown that 
angiotensin activity is increased only in the more 
advanced phases of heart disease. 35 The dependence 
of the increase in renal thromboxane formation on 
angiotensin activation is underlined by its positive 
correlation with PRA, as observed in our study. 
Even if the values of PGF2~ and TXB2 excretion 
were homogeneously distributed within the groups 
and the differences among the classes were highly 
significant, this study was not designed as prospec- 
tive one. As a consequence, the urinary excretion of 
vasoconstrictive eicosanoids cannot be taken as a 
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predictive index of cardiac decompensation. None- 
theless, because the increase in urinary WXB 2 and 
urinary PGF2~ was constantly associated with pro- 
gressive severity in the course of heart disease, our 
results strongly suggest hat the increased renal for- 
mation of the vasoconstrictor eicosanoids and their 
renal effects should be included among the mecha- 
nisms involved in the aggravation of heart disease. 
Therefore the inhibition of vasoconstrictive pros- 
tanoids and particularly that of the more powerful 
TXA 2 may be considered in the future treatment of 
more severe cases of CHF because this inhibition 
may reduce renal vasoconstriction. 36
We thank Carlo Patrono (Istituto di Farmacologia, Universit~ 
di Chieti, Italy) for his generous gift of PGF2~ antiserum and Lu- 
ciano Caprino (Istituto di Igiene, Universit~ Cattolica del Sacro 
Cuore, Rome, Italy) for the TXB2 antiserum. 
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